To further explore the immunological relevance of GSDMD in cancer, we investigated its association with three key biomarkers of immunotherapy response: tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) gene expression. This evidence concerns the gene GSDMD and neoplasm.